Karyopharm Therapeutics reported $6.31M in Interest Expense on Debt for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Interest Expense On Debt Change
Abbott ABT:US $ 106M 25M
Amgen AMGN:US $ 328M 33M
Biocryst Pharmaceuticals BCRX:US $ 24.02M 0.18M
Bristol Myers Squibb BMY:US $ 313M 13M
Eli Lilly And LLY:US $ 81.2M 3.7M
Epizyme EPZM:US $ 380K 10K
Karyopharm Therapeutics KPTI:US $ 6.31M 371K
Nektar Therapeutics NKTR:US $ 7.23M 0.3M
Novartis NOVN:VX 202M 1000K
Novartis NVS:US $ 202M 1M
Pfizer PFE:US $ 293M 29M
Regeneron Pharmaceuticals REGN:US $ 13.1M 0.5M
Tg Therapeutics TGTX:US $ 3.02M 0.35M
YTE INCY:US $ 0.68M 0M